Ask the expert: Are online innovations the future of Parkinson’s treatment?
Author: Sophie BatesPublished: 14 May 2020
Prep: Cook: Serves:
In the latest in our Ask the Expert series, we speak with neurologist Joaquim Ferreira, about the importance of online resources for people with Parkinson’s during the Covid-19 pandemic and how the crisis has led to new forms of clinical communication
Could you tell us how online therapies for people with Parkinson’s are evolving?
Parkinson’s is complex in its clinical presentation – symptoms vary and the condition is not easy to understand, even by healthcare professionals. We are learning that simple aspects regarding the way the diagnosis is made and communicated have prognostic implications, so educating the Parkinson’s community is extremely important.
New healthcare concepts of multidisciplinary and home or community-based interventions are being evaluated in an attempt to define the best way of combining different therapeutic interventions. These new healthcare models include education components and should be addressed in the same way as other health conditions. Likewise, the use of web-based interventions appears as an efficient way to target and hopefully benefit many people with Parkinson’s.
Why is accessing online information about Parkinson’s particularly important during the Covid-19 crisis?
Parkinson’s is a condition that needs continuous follow-up and management, so it’s critical to maintain care and monitoring even when we cannot access clinics in the same way. Keeping up therapeutic programmes is very important to avoid losing the benefits. We have been learning that non-pharmacological treatments – for instance, physiotherapy and speech therapy, have a duration of effect like any drug, so once they are stopped, the effects start to disappear. In the same way that we should not stop taking anti-parkinsonian medication (like drugs that release dopamine or mimic the action of dopamine) without professional advice, therapeutic treatments shouldn’t be stopped.
What role can other online resources play for people with Parkinson’s during the crisis?
The available resources are not enough for the mission we have. Not everything during the pandemic has been negative – this period has forced us to discover new ways that we can be involved in the care of individuals. The use of online tools has allowed us to perform consultations and therapeutic sessions – and we have been able to conclude surprisingly quickly that these tools work.
In terms of the future, online resources will allow a better documentation of what happens in the daily routines of people with Parkinson’s. Physicians will be able to access the real data of individuals from the information collected during face-to-face consultations, which will mean a ‘closer’ follow up – merging outpatient consultations with online interventions and support. So, in my opinion, online visits and sessions are here to stay.
You are the founder of neurological disorders centre Campus Neurológico Sénior (CNS). Could you tell us about the CNS Academy videos and how they benefit people with Parkinson’s?
The main purpose of CNS is to reunite quality clinical activity, leading research projects and training health professionals. The CNS Academy videos present the great work being done by our professionals and highlight our perception that there’s still a huge need for simple and high-quality information for everyone with Parkinson’s. We created these videos because we felt compelled to share the expertise of our dedicated and highly trained professionals – so that others can benefit from their knowledge.
The topics – which were suggested by healthcare professionals working at CNS – try to cover the most frequent and relevant problems that can be addressed by cartoons. They include educational videos on how to manage medication, home safety, how to help the caregiver, speech problems, gait problems etc. The videos’ objective is not just to propose simple tips, but to promote the increase of physical and cognitive training at home, to complement all other interventions applied by professionals in clinics.
How can people ensure that the information they find online about Parkinson’s is accurate and up to date?
It can be extremely difficult to differentiate between high quality data and misinformation. The easiest and most effective way to filter the good from bad is to always favour information published through associations – for instance, the European Parkinson’s Disease Association (EPDA), Parkinson’s Foundation, or organisations with scientific boards validating their content.
It’s important to be cautious when reading news that presents amazing or almost miraculous treatments. We all hope that in the near future we will have huge therapeutic achievements to share – but they will be presented through publications in scientific journals, scientific societies or congresses, and not posted on the web by people who do not have a solid scientific curriculum.
This difficult period reinforces the need for a close and fruitful collaboration between all. It clarifies the need to be humble when dealing with our health and the uncertainties we still have in many fields of knowledge. These strange and unexpected times will end soon, and we should learn from them.
Need to know
Joaquim Ferreira is a neurologist based in Lisbon, Portugal. He has worked in the field of movement disorders and Parkinson’s for the past 25 years and is a professor of neurology and clinical pharmacology at the University of Lisbon. He is also the founder of Campus Neurológico Sénior (CNS) in Portugal, a neurological disorders centre that focuses on multidisciplinary care for people with Parkinson’s.
For more advice on living well with Parkinson’s, please visit the EPDA website.
Parkinson’s prevalence expected to increase by 18% in next seven years
Aging UK population could see increase in Parkinson’s over time
2 days ago
Diesel exhaust fumes may increase the risk of Parkinson’s, study suggests
A new study by researchers in the US has found evidence that chemicals in diesel exhaust fumes can damage brain cells – and potentially increase the risk of Parkinson’s. As part of the study – published in ‘Toxicological Sciences’ – researchers tested the effects of diesel exhaust fumes on zebrafish, as their neurons interact in a similar way to those of humans. The researchers found that after being exposed to the chemicals, the zebrafish had fewer cells that dispose of toxic build-up of the protein alpha-synuclein, which occurs in Parkinson’s. The researchers replicated the experiment with cultured human cells and found similar results. Dr Jeff Bronstein, a professor of neurology at the University of California, Los Angeles (UCLA), US, said: “Overall, this report shows a plausible mechanism of why air pollution may increase the risk of Parkinson’s disease.”
Can Covid-19 increase the risk of developing Parkinson’s?
Parkinson’s could be caused or modulated by infections like Covid-19, a new study suggests – though more evidence is needed to draw a definitive conclusion. As part of the study, researchers from the Federal University of São Paulo, Brazil, drew on previous findings to support their hypothesis. For example, studies in mice have found that infection with some strains of influenza could cause neural changes similar to those in Parkinson’s. Furthermore, people born during or around the 1918 influenza pandemic were over twice as likely to develop Parkinson’s than those born in the decades before or after. Patrik Brundin, co-editor-in-chief of the Journal of Parkinson’s Disease, said that while it’s “too early to know what the long-term consequences of Covid-19 will be on the brain, the clinical psychiatry and neurology research communities definitely need to be vigilant in monitoring how those who recover from moderate and severe Covid-19 fare in…
New Parkinson’s trial platform could “dramatically speed up the search for a cure”
Scientists have proposed the use of a multi-arm, multi-stage trial platform (MAMS) to assess different potential treatments for Parkinson’s and help progress the search for a cure. This would depart from conventional clinical procedures, allowing several potential treatments to be assessed simultaneously. In a continuous process, each treatment ‘arm’ is evaluated and unsuccessful ‘arms’ of the trial are dropped, enabling a far more cost and time efficient system. Currently, MAMS are used to evaluate treatments for certain types of cancer – and work is underway to develop MAMS for other neurodegenerative conditions. Camille Buchholz Carroll, associate professor at the University of Plymouth, UK, and study author, said that MAMS trials could “dramatically speed up the search for a cure”. She said: “We have the opportunity to learn from the experience in these other conditions and design a new trial that will work for people with Parkinson’s.”